Showing 4701-4710 of 5771 results for "".
- CooperVision Biofinity Toric Multifocal Contact Lenses Now Available Nationwide in the UShttps://modernod.com/news/coopervision-biofinity-toric-multifocal-contact-lenses-now-available-nationwide-in-the-us/2477786/CooperVision has announced that its new Biofinity toric multifocal contact lenses are now available nationwide in the United States. “Amid the COVID-19 pandemic, we understand that eye care practices are operating under various circumstances, and for many, fitting contact lenses still may
- EyePoint Pharmaceuticals Presents Data Showcasing Dexycu at the ASCRS Virtual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-presents-data-showcasing-dexycu-at-the-ascrs-virtual-meeting/2477784/EyePoint Pharmaceuticals announced the presentation of positive retrospective case study data supporting Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following ocular surgery. The data were presented in three electronic posters and one oral pape
- Allergan to Share New Safety and Efficacy Data on Recently Approved Durysta at ASCRS Virtual Meetinghttps://modernod.com/news/allergan-to-share-new-safety-and-efficacy-data-on-recently-approved-durysta-at-ascrs-virtual-meeting/2477773/Allergan, which is now part of AbbVie, will present new glaucoma research at the American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting on May 16. Data will include four virtual paper presentations analyzing safety and efficacy across several subgroups from the phase 3
- VSY Biotechnology Says It Has Developed a New Drug to Treat COVID-19https://modernod.com/news/vsy-biotechnology-says-it-has-developed-a-new-drug-to-treat-covid-19/2477774/Ophthalmic company VSY Biotechnology announced that its research center has developed a new drug, TR-C 19, to treat COVID-19. Studies have shown that TR-C 19 can neutralize the virus isolated under laboratory conditions, according to a company news release. The drug is now at the authority
- Prevent Blindness Unveils New Brand Identity, Logo and Websitehttps://modernod.com/news/prevent-blindness-unveils-new-brand-identity-logo-and-website/2477772/Prevent Blindness announced the launch of its new brand identity, logo, and website. The launch coincides with the organization’s new “Be a Visionary” campaign: a call to action to join in the sight-saving efforts of Prevent Blindness. The new identity is designed to refl
- Blanchard Contact Lenses Launches Onefit Spotlight Programhttps://modernod.com/news/blanchard-contact-lenses-launches-onefit-spotlight-program/2477769/Blanchard Contact Lenses has announced the launch of their new Onefit Spotlight program, which was designed to highlight the great work of those who are fitting the Onefit family of scleral lenses. Prac
- New Data on the Pharmacokinetic Profile of Tepezza Reinforce the Labeled Dosing Regimenhttps://modernod.com/news/new-data-on-the-pharmacokinetic-profile-of-tepezza-reinforce-the-labeled-dosing-regimen/2477768/Horizon Therapeutics announced new data that provide important insights into the mechanisms of Tepezza (teprotumumab-trbw), illustrating its pharmacokinetic (PK) profile and supporting the dosing regimen established in the labeling for the treatment of Thyroid Eye Disease (TED). A separate abstra
- New Visionix VX65 Digital Phoropter Helps ECPs Meet Social Distancing Recommendationshttps://modernod.com/news/new-visionix-vx65-digital-phoropter-helps-ecps-meet-social-distancing-recommendations/2477756/Luneau Technology USA announced the expansion of its Visionix product line with the addition of the Visionix VX65 digital phoropter. With the majority of refractions are still being conducted with a manual phoropter, the VX65 provides a smooth transition for eye care professionals looking to init
- Novavax Granted Up to $384 Million in New CEPI Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-granted-up-to-384-million-in-new-cepi-funding-for-covid-19-vaccine-candidate/2477747/Novavax announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of the company’s vaccine candidate NVX-CoV2373 against SARS-CoV-2. In Ap
- InMed Files PCT Patent Application for Neuroprotection in Glaucomahttps://modernod.com/news/inmed-files-pct-patent-application-for-neuroprotection-in-glaucoma/2477748/InMed Pharmaceuticals announced that it has filed a Patent Cooperation Treaty (PCT) application pertaining to the potential of cannabinoids in the prevention of neuron damage associated with glaucoma. The patent application, entitled “Compositions and Methods for Use of Cannabinoids